Synergism of antitumor action of dioxadet and cisplatin in model of ascitic ovarian tumor
Abstract
Comparative antitumor activity of cytostatics dioxadet, cisplatin and their combination was studied in model of ascitic ovarian tumor in 38 female Wistar rats. Ascitic ovarian tumor was transplanted intraperitoneally at amount of 5 × 106 tumor cells per rat. Dioxadet and
cisplatin were administered intraperitoneally at their single maximal tolerable doses 48 hours after the tumor transplantation: 1,5 and 4,0 mg/ kg b.w., respectively. Drug combination of dioxadet and cisplatin administered by the same way but at one half of maximal tolerable doses. Antitumor effects of the drugs were estimated by increasing life span of the animals. In control group without treatment the average life span was 16 ± 6,3 days. Dioxadet and cisplatin showed comparable antitumor activity increasing the average life span by 63,1 % and 48,1 %, correspondingly. Drugs combination showed synergistic effect increasing average life span by 107,5 % (p<0,05). Moreover, combination
of dioxadet and cisplatin are characterized by less toxicity compared with cisplatin applied in maximal tolerable dose.
cisplatin were administered intraperitoneally at their single maximal tolerable doses 48 hours after the tumor transplantation: 1,5 and 4,0 mg/ kg b.w., respectively. Drug combination of dioxadet and cisplatin administered by the same way but at one half of maximal tolerable doses. Antitumor effects of the drugs were estimated by increasing life span of the animals. In control group without treatment the average life span was 16 ± 6,3 days. Dioxadet and cisplatin showed comparable antitumor activity increasing the average life span by 63,1 % and 48,1 %, correspondingly. Drugs combination showed synergistic effect increasing average life span by 107,5 % (p<0,05). Moreover, combination
of dioxadet and cisplatin are characterized by less toxicity compared with cisplatin applied in maximal tolerable dose.
About the Authors
V. G. Bespalov
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
A. A. Zhabin
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
A. N. Stukov
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
O. A. Beliaeva
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
If. G. Murazov
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
A. L. Semenov
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
S. A. Kon’kov
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
I. M. Krylova
N.N. Petrov Research Institute of Oncology of the Ministry of Health and Social Development, St. Petersburg
Russian Federation
Russian Federation
References
1. Беспалов В.Г., Беляева О.А., Панченко А.В. и др. Противоопухолевое действие диоксадэта в сравнении с цисплатином на модели асцитной опухоли яичника у крыс // Вопросы онкологии. 2011. Т. 57, № 6. С. 770–774.
2. Гершанович М.Л., Филов В.А., Котова Д.Г. и др. Результаты кооперированного клинического изучения противоопухолевого препарата диоксадэт по II фазе // Вопросы онкологии. 1998 Т. 44, № 2. С. 216–220.
3. Лошадкин Н.А., Курляндский Б.А., Дарьина Л.В. Токсикология алкилирующих соединений // Общая токсикология / Под ред. Б.А. Курляндского, В.А. Филова. М.: Медицина, 2002. С. 236–257.
4. Пенсон Р.Т. Рак яичников // Чебнер Б.Э., Линч Т.Д., Лонго Д.Л. Руководство по онкологии / Пер. с англ.; Под ред. В.А. Хайленко. М.: МЕДпресс-информ, 2011. С. 517–531.
5. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Под ред. Р.У. Хабриева. М.: Медицина, 2005. С. 637–651.
6. Стуков А.Н., Гершанович М.Л., Бланк М.А. и др. Противоопухолевые лекарственные средства. СПб.: NIKA, 2011. С. 185–186, 563–570.
7. Урманчеева А.Ф. Лекарственная терапия рецидивирующего рака яичника (обзор литературы) // Сибирский онкологический журнал. 2010. № 3 (39). С. 28–33.
8. Чебнер Б.Э. Алкилирующие средства и производные платины // Чебнер Б.Э., Линч Т.Д., Лонго Д.Л. Руководство по онкологии / Пер. с англ.; Под ред. В.А. Хайленко. М.: МЕДпресс-информ, 2011. С. 69–75.
9. Colombo N., Gore M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy // Crit. Rev. Oncol. Hematol. 2007. Vol. 64. P. 129–138.
10. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012 // CA Cancer J. Clin. 2012. Vol. 62. P. 10–29.
11. Todd R.C., Lippard S.J. Inhibition of transcription by platinum antitumor compounds // Metallomics. 2009. Vol. 1. P. 280–291.
Review
For citations:
Bespalov V.G., Zhabin A.A., Stukov A.N., Beliaeva O.A., Murazov I.G., Semenov A.L., Kon’kov S.A., Krylova I.M. Synergism of antitumor action of dioxadet and cisplatin in model of ascitic ovarian tumor. Siberian journal of oncology. 2013;(1):42-46. (In Russ.)
Views:
707
Email this article 
